Highest-materiality recent filing
Syra Health posts first profitable quarter in Q1 2026; net income $241K, EPS $0.02, revenue up 22%
Net income of $241,000 vs net loss of $(472,265) in Q1 2025; EPS $0.02 vs ($0.04).
Syra Health FY2025 net loss down 76%; Population Health revenue up 157% to $5.3M
FY2025 revenue $7.2M (-9% YoY); net loss improved 76% to ($896K) from ($3.8M).
Syra Health appoints Gregory R. Alexander as CEO effective Jan 5, 2026
New CEO Gregory R. Alexander receives $251k base salary, 30% target bonus, and 110,537 RSUs.
Syra Health Q3 revenue falls 26% to $1.7M; population health up 96%, net loss down 46%
Revenue $1.7M, down from $2.3M YoY due to federal spending cuts.
Syra Health Q2 net loss narrows 95% to $64K; gross margin surges to 38.7%
Net loss of $64K ($0.01 EPS) vs $1.4M loss ($0.21 EPS) in Q2 2024; adjusted EBITDA improved to ($54K) from ($1.4M).
Syra Health terminates CEO Deepika Vuppalanchi for cause; CFO appointed interim CEO
Board terminated CEO Deepika Vuppalanchi for cause on June 13, 2025.
Syra Health board launches national CEO search; Vuppalanchi interim
Board initiates a national search for a new CEO to succeed current CEO Dr. Deepika Vuppalanchi.
Syra Health Q1 revenue $1.9M (+6% YoY); net loss narrows to ($472K); withdraws 2025 guidance
Revenue $1.9M (+6% YoY); Population Health revenue tripled to $1.2M.
Syra Health FY 2024 revenue $8.0M (+45% YoY); Q4 net loss nearly halved to $504K; PopHealth up 132%
FY 2024 revenue $8.0M (+45% YoY); net loss $3.8M vs $2.9M in 2023.
Syra Health Executive Chairman and President Sandeep Allam passes away
Notified on January 15, 2025 of Sandeep Allam's death.
Syra Health regains Nasdaq compliance on minimum equity requirement
Received Nasdaq deficiency notice Aug 13, 2024 for failing minimum $2.5M stockholders' equity.
Syra Health reports Q3 2024 revenue $2.3M (+42% YoY); net loss narrows 69% sequentially to $417K
Revenue $2.3M, up 42% YoY from $1.6M; Population Health +36%, Healthcare Workforce +54%.
Syra Health receives Nasdaq delisting notice for bid price below $1.00 for 30 consecutive days
Nasdaq notified Syra Health on Oct 18, 2024 that its common stock bid price closed below $1.00 for 30 business days, violating Listing Rule 5550(a)(2).
Nasdaq notified Syra Health of non-compliance with stockholders' equity minimum of $2.5M (Listing Rule 5550(b)(1)).
Syra Health Q2 revenue $2.0M (+101% YoY); net loss widens to $1.4M
Revenue $2.0M vs $1.0M in Q2 2023; Population Health grew 276% YoY, Healthcare Workforce 66%.
Syra Health Q1 revenue up 47% to $1.7M, net loss widens to $1.4M; FY2024 guidance $9-11M
Revenue $1.7M vs $1.2M Q1 2023; Population Health grew 212% YoY; Healthcare Workforce up 28%.
Syra Health 2023 revenue $5.5M, net loss $2.94M; projects 64-100% growth in 2024
FY2023 revenue $5.5M, net loss $(2.94M), vs $5.6M and $(2.12M) in 2022.
Syra Health Q3 revenue up 4% to $1.58M; net loss flat at $354K; Digital Health posts first revenue
Revenue $1.58M (+4% YoY); Digital Health unit generated first revenues of $131,356.
Syra Health prices upsized IPO of 1.615M units at $4.125/unit, raises ~$6.7M gross
IPO units priced at $4.125 each: one share Class A common + one warrant (exercise $6.50, 5-year term).
the Board of Directors of the Company appointed Priya Prasad, the Company’s CFO and COO, as interim CEO.
On April 25, 2025, Andrew Dahlem resigned from the Board of Directors of Syra Health Corp. (the “Company”) for personal reasons.
On March 27, 2024, the Board of Directors of Syra Health Corp. (the “Company”) appointed Priya Prasad, the Company’s COO and CFO as a director of the Company.
Effective as of October 3, 2023, each of Sherron Rogers, Andrew Dahlem, Vijayapal Reddy, Ketan Paranjape, and Avutu Reddy were appointed to serve as members of Syra Health Corp.'s (the “Company’s”) board of directors (the “Board”).
Effective as of October 3, 2023, each of Sherron Rogers, Andrew Dahlem, Vijayapal Reddy, Ketan Paranjape, and Avutu Reddy were appointed to serve as members of Syra Health Corp.'s (the “Company’s”) board of directors (the “Board”).
Effective as of October 3, 2023, each of Sherron Rogers, Andrew Dahlem, Vijayapal Reddy, Ketan Paranjape, and Avutu Reddy were appointed to serve as members of Syra Health Corp.'s (the “Company’s”) board of directors (the “Board”).
Effective as of October 3, 2023, each of Sherron Rogers, Andrew Dahlem, Vijayapal Reddy, Ketan Paranjape, and Avutu Reddy were appointed to serve as members of Syra Health Corp.'s (the “Company’s”) board of directors (the “Board”).
Effective as of October 3, 2023, each of Sherron Rogers, Andrew Dahlem, Vijayapal Reddy, Ketan Paranjape, and Avutu Reddy were appointed to serve as members of Syra Health Corp.'s (the “Company’s”) board of directors (the “Board”).
Max materiality 0.80 · Median 0.65 · Most common event earnings